Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 72603-875

This text provides a comparison of the risk of venous thromboembolism (VTE) associated with Yasmin relative to LNG-containing combined oral contraceptives (COCs). It includes data from various studies and adjustment factors such as smoking, hypertension, obesity, family history, age, BMI, duration of use, VTE history, and more. The risk ratios are displayed on a logarithmic scale, where a ratio < 1 indicates a lower risk with Yasmin and a ratio > 1 indicates an increased risk. References to the studies mentioned are also provided.*

The text provides a figure showing the likelihood of developing a venous thromboembolism (VTE) in different scenarios: non-pregnant ranges for non-users of combined oral contraceptives (COC), COC users, pregnancy, and postpartum ranges. The data includes the number of women with a blood clot out of 10,000 women years. The figure illustrates that the incidence of VTE varies depending on the specific scenario and highlights the increased risk during certain periods such as pregnancy and postpartum. The text also mentions that the pregnancy data is based on the actual duration of pregnancy in reference studies, with assumptions that the duration is nine months and the rate of VTE is between 7 to 27 per 10,000 women years.*

This text provides data on the comparison of ever vs. never use of combined oral contraceptives (COC) and current use vs. never use of COC from various studies. The text includes the authors, study names, and effect estimates such as odds ratios (OR), relative risks (RR), and hazard ratios (HR) with corresponding confidence intervals. The studies mentioned are NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, The Nurses' Health Study II, Oxford Family Planning Study, and Danish Sex Hormone Register Study. The data presented here can be used to evaluate the association between COC use and certain health outcomes.*

This is a breakdown of blood clot risk in women based on their pregnancy status and use of contraceptives. The data provides ranges of blood clot occurrences per 10,000 Women Years (WY) for non-pregnant non-contraceptive pill users, contraceptive pill users, pregnant women, and postpartum women within 12 weeks after childbirth. Additionally, it mentions a model assumption that estimates blood clot rates for pregnancy as 7 to 27 per 10,000 WY based on a nine-month pregnancy duration.*

This text is a description of a pouch containing a blister pack with 28 tablets of oral contraceptive. The tablets have a composition of 3 mg/0.02 mg. The product aims to prevent pregnancy and does not protect against HIV or other sexually transmitted diseases. The NDC number for this product is 72603-875-01.*

This is a medication package containing drospirenone and ethinyl estradiol tablets USP, with a dosage of 3 mg/0.02 mg. The product is an oral contraceptive designed to prevent pregnancy. The package includes 3 pouches, each containing a blister pack of 28 tablets - 24 light pink to pink tablets with active ingredients and 4 green inert tablets. The recommended dosage is one tablet daily for 28 consecutive days per menstrual cycle. Patient information labeling and day label stickers are provided in each pouch. The medication should be stored at 20°C to 25°C and kept out of reach of children due to lack of child resistance. The product is manufactured by Aurobindo Pharma Limited in India for Northstar Rx LLC in Memphis, Tennessee.*